Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.5521
-0.0459 (-7.68%)
May 29, 2025, 4:00 PM - Market closed

Kairos Pharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
3.621.270.090.440.07
Cash & Short-Term Investments
3.621.270.090.440.07
Cash Growth
8940.00%1267.74%-78.72%498.63%-
Prepaid Expenses
0.060.040.01--
Other Current Assets
2.382.86---
Total Current Assets
6.054.170.10.440.07
Other Intangible Assets
0.180.220.380.540.7
Long-Term Deferred Charges
1.711.380.480.06-
Total Assets
7.945.770.971.040.78
Accounts Payable
0.810.992.41.631.55
Short-Term Debt
--000.39
Total Current Liabilities
0.810.992.411.631.94
Long-Term Debt
--0.640.58-
Total Liabilities
0.810.993.042.221.94
Common Stock
0.020.010.010.010.1
Additional Paid-In Capital
16.7113.584.123.212.08
Retained Earnings
-10.08-8.82-6.21-4.4-3.35
Shareholders' Equity
7.134.78-2.08-1.18-1.17
Total Liabilities & Equity
7.945.770.971.040.78
Total Debt
--0.640.590.39
Net Cash (Debt)
3.621.27-0.55-0.15-0.32
Net Cash Per Share
0.290.11-0.05-0.01-0.04
Filing Date Shares Outstanding
16.8516.6910.5610.339.15
Total Common Shares Outstanding
15.8313.7410.5610.339.15
Working Capital
5.253.18-2.3-1.2-1.87
Book Value Per Share
0.450.35-0.20-0.11-0.13
Tangible Book Value
6.954.55-2.46-1.72-1.87
Tangible Book Value Per Share
0.440.33-0.23-0.17-0.20
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q